IL1A and rectal cancer: Consistently, the presence of inflammatory CAFs in pre-therapeutic patient biopsies resulted in poor chemoradiotherapy response and low IL-1α receptor antagonist serum levels, which enhances IL-1 signaling and predisposes inflammatory CAFs to TIS, correlated with poor prognosis in rectal cancer patients [184].